HS Biopharm acquires Kyungnam Pharm

Published: 2007-07-12 06:59:00

Updated: 2007-07-12 06:59:00

HS Biopharm, local human placenta manufacturer, said on July 9 that it acquired 100 percent stake of Kyungnam Pharm owned by Green Cross Corporation (GCC) and GCC holding.

An official of HS Biopharm said that for the deal, the company invested 24.5 billion won and the acquisition will make it ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK